Brian James Dewar1, Kayvan Keshari1, Rex Errol Jeffries1, Lee M. Graves2, Jeffrey M. Macdonald1
1Biomedical Engineering, Univ. of North Carolina, Chapel Hill, NC, USA; 2Pharmacology, Univ. of North Carolina, Chapel Hill, NC, USA
Drug resistance to Imatinib often develops in CML. Here we characterized metabolic differences using NMR, comparing an Imatinib-resistant cell model, MyLR, to a Imatinib-sensitive parental cell line, MyL. Here we describe the first such example of elevated phosphocreatine levels in drug -resistant leukemia cell using conventional MRS metabolomics and NMR compatible bioreactor.